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Mobilized peripheral blood has become the primary source of hematopoietic stem and progenitor cells (HSPCs) for stem cell 
transplantation, with a 5-day course of granulocyte colony-stimulating factor (G-CSF) as the most common regimen used for 
HSPC mobilization. The CXCR4 inhibitor plerixafor is a more rapid mobilizer, yet not potent enough when used as a single agent, 
thus emphasizing the need for faster acting agents with more predictable mobilization responses and fewer side effects. We 
sought to improve hematopoietic stem cell transplantation by developing a new mobilization strategy in mice through combined 
targeting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin. Rapid and synergistic mobilization of 
HSPCs along with an enhanced recruitment of true HSCs was achieved when a CXCR2 agonist was coadministered in conjunction 
with a VLA4 inhibitor. Mechanistic studies revealed involvement of CXCR2 expressed on BM stroma in addition to stimulation 
of the receptor on granulocytes in the regulation of HSPC localization and egress. Given the rapid kinetics and potency of HSPC 
mobilization achieved by the VLA4 inhibitor and CXCR2 agonist combination in mice compared with currently approved HSPC 
mobilization methods, the combination represents an exciting potential strategy for clinical development in the future.
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Introduction
In postnatal mammals, the vast majority of hematopoietic stem 
and progenitor cells (HSPCs) reside in the protective environment 
of the bone marrow (BM) (1, 2). Accordingly, only very few HSPCs 
can be found in the periphery, primarily in blood and spleen, during 
homeostasis (3). A wide variety of stimuli has been identified that 
elicits HSPC egress from the marrow, a phenomenon referred to 
as mobilization (4). Despite its significance and the preclinical 
discovery of various approaches to lure HSPCs into the circulation 
during the past 2 decades, the armamentarium of clinical mobili-
zation remains sparse. Thus, granulocyte colony-stimulating fac-
tor (G-CSF) is the sole agent approved for mobilization of healthy 
donors, whereas in patients chemotherapy and the small molecule 
antagonist of the chemokine receptor CXCR4, AMD3100 (Plerixa-
for), are approved in conjunction with G-CSF (5).
Limitations of currently available clinical regimens provide the 
rationale for the ongoing search for alternative mobilization strat-
egies. Importantly, all approaches described to date target at least 
1 of the 2 major axes mediating HSPC retention: the chemokine 
receptor CXCR4 or the integrin very late antigen 4 (VLA4) (4, 6, 7). 
Inhibition of the interaction between CXCR4 and its chief ligand 
CXCL12 has been extensively studied by us and others (8–13). By 
contrast, targeting of VLA4 and use thereof to release HSPCs from 
the BM has been explored considerably less intensively due to lack 
of suitable small molecule compounds with favorable pharmaco-
logic properties (7, 14).
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Optimal pharmacokinetics and pharmacodynamics were deter-
mined to be associated with subcutaneous administration of the 
CWHM-823 plus tGro-? mixture (Supplemental Figure 1, A and 
B). Time and dose-response analysis revealed no increase in mobi-
lization between 3 mg/kg and 15 mg/kg of CWHM-823, whereas 
peak mobilization was reached approximately 30 minutes after 
the injection (Supplemental Figure 1C).
Complementary to the testing of different VLA4 inhibitors, 
stimulation with tGro-? (CXCL2) was compared with that of the 
alternative CXCR2 ligands CXCL1 (Gro-?) and CXCL8 (IL-8). 
Again, all 3 agonists induced HSPC mobilization when given alone 
as well as in combination with CWHM-823 (Figure 1F). To con-
trol for specificity of the observed effects, CXCR2-KO mice were 
included. As expected, CXCR2 ligands alone did not induce mobili-
zation in CXCR2-KO mice. Mobilization with the VLA4 antagonist 
was higher in absolute numbers yet qualitatively unchanged consid-
ering the higher baseline levels of circulating CFU-C (930 CFU-C/
ml [BALB/cJ CXCR2-KO] versus 300 CFU/ml [BALB/cJ WT] at 
baseline, and 3800 CFU-C/ml [BALB/cJ CXCR2-KO]versus 1300 
CFU-C/ml [BALB/cJ WT] mobilized with CWHM-823). Surpris-
ingly, a decrease in mobilization with CWHM-823 was observed in 
CXCR2-KO mice when CXCR2 ligands were coadministered with 
the VLA4 antagonist. One possible explanation for this is that the 
bioavailability of CWHM-823 is reduced upon administration in 
conjunction with the chemokine as compared with its administra-
tion alone (Supplemental Figure 1B). Lack of specificity for the target 
receptor CXCR2 appears unlikely: in our comprehensive screening 
of tGro-? against a panel of 348 different G protein–coupled recep-
tors, no cross-reactivity of the chemokine with any receptors other 
than CXCR2 was found (Supplemental Table 2).
Properties of mobilized cells. Having established that VLA4 inhi-
bition combined with CXCR2 stimulation achieves superior CFU-C 
mobilization, we compared the repopulating capacity of the grafts 
mobilized with this new regimen, the single agents, or G-CSF (Fig-
ure 2A). For both VLA4 antagonists tested (firategrast and CWHM-
823), a significantly increased blood graft–derived contribution in 
the primary recipients was detected when each antagonist was com-
bined with tGro-? compared with engraftment from blood mobi-
lized by either of the VLA4 antagonists or tGro-? alone (Figure 2B). 
More importantly, despite higher numbers of CFU-Cs mobilized by 
G-CSF (Supplemental Figure 2 and data not shown), the concentra-
tion of repopulating units in the blood of mice mobilized with VLA4 
antagonist plus tGro-? was equal to that of G-CSF. Analysis of sec-
ondary recipients (i.e., evidence of serially repopulating units) con-
firmed virtually identical mobilization potency within the immature 
HSC fraction for G-CSF and VLA4 antagonist plus tGro-? (Figure 
2C). Moreover, in a model of diabetes-associated poor mobili-
zation (10, 35, 36) generated by exposure of mice to the pancreas 
toxic agent streptozotocin, mobilization was better preserved with 
VLA4 antagonist plus tGro-? combination as compared with G-CSF 
(7200 CFU-C/ml in diabetic compared with 22,200 CFU-C/ml in 
healthy mice with G-CSF; 9000 compared with 6350 CFU-C/ml 
with CWHM-823 plus tGro-?, Supplemental Figure 2).
We then performed gene expression profiling of differentially 
mobilized HSPCs. LSK cells isolated from the blood of mice treated 
with AMD3100 (1 hour), G-CSF (5 days), or CWHM-823 plus 
tGro-? (30 minutes) along with LSK cells from BM of untreated 
The chemokine receptor CXCR2 is a critical regulator of 
neutrophil chemotaxis (15). Interestingly, stimulation of CXCR2 
signaling (e.g., with its ligands CXCL1, -2, or -8) has been demon-
strated to result in rapid HSPC mobilization from the BM even 
though the receptor is not expressed on HSPCs themselves (16–
20). The mechanism of HSPC egress after CXCR2 stimulation 
remains controversial.
In this study, we explored the potential of combined target-
ing of VLA4 and CXCR2 signaling as a novel strategy to mobilize 
HSPCs. In addition to being associated with a rapid and remarkably 
synergistic HSPC release, administration of a VLA4 antagonist in 
conjunction with a CXCR2 ligand targeted very primitive, serially 
repopulating HSPCs with high efficiency. Our observations chal-
lenge the notion of limited potential of fast-acting mobilizing agents 
and are particularly relevant in the context of the ongoing debate 
about the vascular versus endosteal localization of stem cells (21–23). 
Moreover, unexpectedly, stromal cells were found to be targeted 
by CXCR2 stimulation along with neutrophils. This contribution 
of both stromal and neutrophilic CXCR2 to the regulation of HSPC 
localization underlies the intricate interplay between nonhema-
topoietic and mature hematopoietic cells for HSPC maintenance.
Results
Combined targeting of VLA4 and CXCR2 results in augmented HSPC 
recruitment. We assessed the mobilization efficiency of a VLA4 
antagonist alone compared with a CXCR2 agonist alone, as well 
as their combined effect in vivo. The previously described small- 
molecule VLA4 inhibitor firategrast (24, 25) along with the natu-
rally occurring truncated form of the CXCR2 ligand Gro-? (tGro-?) 
(26, 27) were used in the initial experiment. As shown in Figure 1, 
combined treatment with both agents resulted in increased num-
bers of circulating WBCs and CFU-Cs of up to 3- and 10-fold, 
respectively (Figure 1, A and B). To circumvent the shortcomings of 
VLA4-targeting compounds hitherto tested as mobilizing agents, 
we selected a series of VLA4 antagonists that had been developed 
based on the structure of the well-known VLA4 inhibitors BIO5192 
(28) and firategrast (24, 25). These compounds (CWHM-822, 
823, 824, 825, and 842; Figure 1C) were synthesized as previously 
described (29–34). Properties of the inhibitors were assessed using 
a colorimetric, cell-free, solid-phase receptor binding assay (SPRA; 
Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI124738DS1) as well 
as a flow cytometry–based soluble VCAM1 binding assay (Figure 
1D). CWHM-823, -824, and -842 showed superior binding affin-
ity to VLA4 compared with firategrast (Figure 1D). CWHM-822 
and -823 had an improved water solubility compared with both 
BIO5192 and firategrast (Supplemental Table 1).
We next tested whether the synergism between VLA4 inhi-
bition and CXCR2 stimulation was a compound class as opposed 
to a compound-specific effect. Therefore, mobilization with 
BIO5192 and firategrast was tested alongside the new compounds, 
CWHM-823 and -842. All 4 inhibitors mobilized HPSCs by them-
selves, whereas the mobilization response was enhanced up to 
3- to 10-fold when combined with tGro-? (Figure 1E), suggesting 
a compound class–specific effect. Firategrast-related CWHM-823 
outperformed the BIO5192-related CWHM-842 in vivo and was 
therefore selected for the majority of our subsequent analyses. 
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CWHM-823 plus tGro-? versus G-CSF had only 53 such genes 
(Supplemental Table 4). By contrast, 694 genes were significantly 
up- or downregulated between AMD3100 and CWHM-823 plus 
tGro-?–mobilized LSK cells despite their very similar kinetics 
of mobilization (Supplemental Table 5). The close relationship 
between CWHM-823 plus tGro-?–mobilized LSK cells, BM- 
resident LSK cells, and G-CSF LSK cells was further evident upon 
mice were examined using microarray analysis. A high degree 
of similarity between the analyzed LSK types was found, with 
AMD3100-mobilized LSK cells being the only group clustering 
somewhat separately from the other 3 using principal compo-
nent analysis (PCA, Figure 2D). In comparison to BM, LSK cells 
mobilized by CWHM-823 plus tGro-? had only 45 genes with 
significantly different expression levels (Supplemental Table 3). 
Figure 1. Targeting VLA4 and CXCR2 to mobilize HSPCs. (A–B) DBA2/J mice were treated with the VLA4 inhibitor firategrast (100 mg/kg, i.v.), the CXCR2 ligand 
tGro-? (2.5 mg/kg, s.c.) or both agents immediately after each other. Blood was analyzed for WBCs (A) and CFU-Cs (B). Data are mean ± SEM, n = 5. ***P < 0.001, 
**P < 0.01, compared with firategrast alone/compared with tGro-? alone. (C) Molecular structures. (D) G2-ALL cells were treated in duplicate with the VLA4 inhibitors 
shown in C. Percent inhibition of VCAM1 binding as compared with untreated samples. Data are mean ± SEM of a single experiment representative of 3 experiments. 
(E) DBA2/J mice were injected with tGro-? (2.5 mg/kg, s.c.), a VLA4 antagonist (3 mg/kg, i.v., for BIO5192, CWHM-823, and -842; 100 mg/kg, i.v., for firategrast), or 
their combination. Controls received vehicle only. Numbers of circulating CFU-Cs and LSK cells were analyzed 0.5 hours after the injection(s). Data are mean ± SEM, 
n = 8–10. ***P < 0.001, **P < 0.01, *P < 0.01, compared with tGro-? alone/VLA4 antagonist alone. (F) HSPC mobilization in CXCR2-KO mice using the CXCR2 ligands 
CXCL1, CXCL2 (tGro-?), and CXCL8 and the VLA4 antagonist CWHM-823 as well as their combinations was compared with that in WT BALB/cJ. Blood CFU-C numbers 
were analyzed at baseline, 15 minutes after injection of CXCR2 ligands (s.c., 1 mg/kg CXCL1 and CXCL8, 2 mg/kg tGro-?), 1 hour after injection of CWHM-823 (s.c., 3 
mg/kg), and 30 minutes after the combined treatment (s.c. injection of each ligand together with CWHM-823 at same doses as single treatments). Data are mean 
± SEM, n = 4–26 in mobilized groups, n = 51–78 in baseline groups. ***P < 0.001, compared with CXCR2 agonist alone/compared with CWHM-823 alone. Statistical 
comparisons were made using linear mixed models in A and B and ANOVA in all others, followed by step-down Bonferroni’s adjustment for multiple comparisons.
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VLA4 antagonist (CWHM-823, 45 minutes prior to tGro-? admin-
istration) did not alter subsequent tGro-?–induced mobilization 
(Figure 3A). In contrast, albeit lower than when both compounds 
were given simultaneously, significantly elevated numbers of cir-
culating CFU-Cs were detected in CWHM-823–mobilized mice 
that had been pretreated with tGro-? as compared with PBS. These 
findings pointed toward CXCR2 targeting as the priming event.
Within the hematopoietic compartment, CXCR2 expression 
was detected almost exclusively in granulocytes, and specifically 
HSCs themselves were CXCR2-negative (Supplemental Figure 
4). Therefore, as expected, when granulocytes were depleted 
from the circulation (Figure 3, B and C), mobilization responses 
to tGro-? alone as well as to the combination of CWHM-823 plus 
tGro-? were completely blunted (Figure 3D).
In order to distinguish between hematopoietic-intrinsic versus 
nonhematopoietic contributions for mobilization with CWHM-
823 plus tGro-?, chimeric animals were generated by transplant-
ing CXCR2-KO or WT BM cells into WT recipients and vice versa, 
WT cells into CXCR2-KO or WT recipients (Figure 4A). Follow-
ing reconstitution, mice were mobilized with CWHM-823 alone, 
tGro-? alone, or the combination. As expected, mobilization with 
the VLA4 antagonist alone was similar in both hematopoietic and 
stromal CXCR2 knockouts (Figure 4B). No HSPC mobilization 
with tGro-? alone was observed in WT recipients reconstituted 
with CXCR2-KO BM (Figure 4C, first and second bars from left). 
Surprisingly, CXCR2-KO recipients engrafted with the WT BM also 
demonstrated attenuated mobilization (Figure 4C, fifth and sixth 
bars from left), indicating an additional contribution of nonhema-
topoietic (stromal) CXCR2 to the tGro-?–induced HSPC egress. 
Moreover, the combination of CWHM-823 and tGro-? mobilized 
HSPCs with almost equal potency in WT recipients of CXCR2-
KO and WT BM (Figure 4D, comparing second and fourth bars 
from left). Mobilization of similar magnitude was also detected 
in CXCR2-KO and WT recipients reconstituted with WT BM. Stim-
ulation of either hematopoietic or stromal CXCR2 was therefore 
sufficient to elicit synergistic mobilization when combined with 
inhibition of VLA4 signaling.
Expression and functional role of CXCR2 in endothelial cells 
(ECs) has been described (38, 39). Our previous studies indicated 
the absence of CXCR2 expression in CXCL12-abundant reticu-
lar cells (CARs, another major cellular player involved in HSPC 
retention) (40, 41). We therefore tested whether CXCR2 ablation 
restricted to ECs would lead to changes in mobilization responses. 
As shown in Figure 4E, mobilization with all 3 regimens (CWHM-
823, tGro-?, and CWHM-823 plus tGro-?) was decreased in 
CXCR2 EC-KO recipients compared with the control group. Most 
pronounced was the effect observed with tGro-? alone.
Role of cellular adhesion. Our studies suggested that stimula-
tion of CXCR2 on either granulocytes or stroma was sufficient 
to recruit as many HSPCs into the circulation as when the target 
receptor was present in both compartments (Figure 4). This led 
us to investigate the role of adhesive cross-stimulatory interaction 
between neutrophils and stroma, likely initiated through exposure 
to the chemokine. Beta 2 integrins LFA1 (ITGAL/ITGB2, CD11a/
CD18) and Mac1 (ITGAM/ITGB2, CD11b/CD18) are well-known 
crucial mediators of neutrophil adhesion to vasculature (42, 43). 
Both have been shown to become activated after CXCR2 stimula-
clustering of the top 1000 differentially expressed genes, which 
demonstrated clear separation of the AMD3100-mobilized LSK 
cells (Figure 2E).
Among the genes significantly enriched in CWHM-823 plus 
tGro-?–mobilized LSK cells, the transcription factors Nr4A1-3 
were identified (Figure 2F). Members of this nuclear receptor 
family have previously been shown to specify a population of 
myeloid-biased long-term repopulating HSCs (37). This is con-
sistent with a relative enrichment of the latter within CWHM-823 
plus tGro-?–targeted HSPCs. Distinct properties of CWHM-823 
plus tGro-? LSK cells were further confirmed when cell cycle sta-
tus of differentially mobilized HSPCs was assessed (Supplemental 
Figure 3). LSK cells mobilized with CWHM-823 were predomi-
nantly quiescent with more than 70% found in the G0 phase and 
approximately 25% and 3% found in G1 and G2/S/M phases of 
the cell cycle, respectively. A much lower proportion of tGro-?– 
mobilized LSKs were not cycling (approximately 50% in G0) and 
virtually no cells were in G2/S/M phase. In contrast, more than 
half of the LSK cells from CWHM-823 plus tGro-?–mobilized 
blood were actively cycling and 5% was found in the G2/S/M 
phase. Thus, LSK cells mobilized with the combination of VLA4 
inhibition and CXCR2 stimulation do not simply represent a mix 
of those mobilized by single agents. Given the rapid kinetics of 
mobilization by these agents when administered alone and in 
combination, the discrepancies between the cell cycle distribution 
imply preferential targeting of distinct LSK species rather than 
changes induced upon exposure to the different agents.
Cellular mechanism of mobilization. We sought to determine 
which of the 2 events, CXCR2 stimulation or VLA4 inhibition, 
needs to occur first and is therefore the priming event for the sub-
sequent response to the second stimulus. Pretreatment with the 
Figure 2. Properties of mobilized HSPCs. (A) Schema for analyzing competi-
tive repopulating capacity. Blood (10 ?l) from CD45.1+ donors (BALB/cJ, n = 2–3) 
mobilized with G-CSF (9 doses every 12 hours, 100 ?g/kg per dose), tGro-? (2.5 
mg/kg, 15 minutes after s.c. injection), VLA4 antagonist firategrast (100 mg/
kg, 1 hour after s.c. injection), and CWHM-823 (3 mg/kg, 1 hour after s.c. injec-
tion), or the combination of tGro-? and VLA4 antagonist (dosed as indicated 
for single injections, 30 minutes after simultaneous injection) was mixed with 
CD45.2+ competitor BM cells (BALB/cJ, n = 2 donors, 2.5 × 105 cells per recipient) 
and transplanted into lethally irradiated primary CD45.2+ hosts (BALB/cJ, n = 
8–10 recipients). (B) Percent CD45.1+ donor cells within the CD45+CD3– compart-
ment of blood was evaluated 20 weeks after transplantation. Data are mean ± 
SEM, n = 8–10. ***P < 0.001 compared with VLA4 antagonist alone/compared 
with tGro-? alone. (C) BM from the primary recipients was harvested, pooled, 
and transplanted into lethally irradiated secondary recipients (CD45.2+ BALB/
cJ, 2.5 × 106 per recipient). The percentage of donor-derived cells in the blood of 
secondary recipients 18 weeks after transplantation is shown. Data are mean 
± SEM, n = 5 and are not significantly different. *P < 0.05. (D–F) LSK cells were 
sorted from the blood of DBA/2J mice mobilized with G-CSF (9 doses every 12 
hours, 100 ?g/kg per dose, n = 3), AMD3100 (5 mg/kg, 1 hour after injection, 
n = 3), or CWHM-823 plus tGro-? (3 mg/kg and 2.5 mg/kg, 30 minutes after 
simultaneous s.c. injection, n = 3). LSK cells from steady-state BM were 
included as control. Total RNA from sorted cells was subjected to microarray 
expression analysis. (D) Principal component analysis (PCA) of mRNA expres-
sion of different LSK species. (E) Corresponding hierarchical clustering map. 
(F) Normalized expression values for the genes Nr4A1-3. Each source/treat-
ment group included n = 3 samples (pooled from up to 6 donors). Statistical 
comparisons were made using ANOVA, followed by step-down Bonferroni’s 
adjustment for multiple comparisons.
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tion (44–46) and have been previously implicated in CXCR2- and 
G-CSF–triggered mobilization (19, 47, 48).
At baseline, no significant hematological changes were found 
in mice lacking LFA1 (CD11a-KO) or Mac1 (CD11b-KO) except 
for a slight increase in circulating neutrophils in CD11a knock-
outs (Figure 5, A–C). Mobilization of CFU-C with CWHM-823 
was approximately doubled in CD11a- or CD11b-deficient mice, 
whereas both strains’ response to tGro-? alone was the same as in 
WT mice, despite a dramatic neutrophilia induced in the CD11a-
KO mice in response to tGro-? (Figure 5B). The response to the 
combination treatment was significantly attenuated (Figure 5C).
Role of proteases. Considering the fact that CXCR2 is not 
expressed on the surface of the HSPCs themselves, we next 
addressed the question of the molecular crosstalk initiated by 
CXCR2 stimulation and how it enables HSPC egress. Previous 
reports aiming to elucidate the mechanism of tGro-? and AMD3100 
Figure 3. Granulocytes are indispensable for tGro-induced mobilization. (A) Effect of different sequences of injection. Two groups of BALB/cJ mice received 
pretreatment with PBS or tGro-? (2.5 mg/kg, s.c.) 15 minutes prior to the injection of CWHM-823 (3 mg/kg, s.c.). Accordingly, 2 other groups were pretreated 
with PBS or the VLA4 antagonist (3 mg/kg CWHM-823, s.c.) 45 minutes prior to tGro-? (2.5 mg/kg, s.c.) injection. A fifth group received a simultaneous injection 
of CWHM-823 plus tGro-? at the indicated doses. At 15 and 60 minutes after the administration of the second compound (or the simultaneous injection in the 
control group), circulating CFU-C numbers were measured. Each bar is mean ± SEM, n = 4–5. ***P < 0.001, **P < 0.01, *P < 0.05. (B–D) For transient depletion 
of blood neutrophils, mice were pretreated with an anti-Gr1 antibody in vivo (200 ?g/mouse, i.v.) 36 hours prior to mobilization with tGro-? (2.5 mg/kg, s.c., time 
point 15 minutes), CWHM-823 (3.0 mg/kg, s.c., time point 60 minutes), or the combined agents (doses same as for separate treatments, time point 30 minutes). 
Nonmobilized mice were used as controls (baseline). Moreover, all 4 conditions were analyzed in cohorts that had been pretreated with a control antibody (200 
?g/mouse, i.v.). (B) Representative scatter plot analyses of unmobilized blood using flow cytometry, with granulocytes virtually absent in anti-Gr1–treated mice. 
(C–D) Numbers of circulating neutrophils (C) and CFU-Cs (D). Each bar is mean ± SEM, n = 7–9. ***P < 0.001, **P < 0.01. Statistical comparisons were made using 
ANOVA, followed by step-down Bonferroni’s adjustment for multiple comparisons. Logarithm transformation was performed for the data in C and D.
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plus tGro-?–induced HSPC release suggested critical involvement 
of the matrix metalloprotease 9 (MMP9) (49–52). Therefore, we 
compared mobilization with the combination of CWHM-823 plus 
tGro-? against AMD3100 plus tGro-? as well as single agent treat-
ments in MMP9-KO mice on both FVB and C57BL/6 (B6) back-
ground (Supplemental Figure 5, A and B). In addition, a pharma-
cologic model in the form of a broad-spectrum MMP inhibitor, 
batimastat, was employed (Supplemental Figure 5C). Baseline 
circulating HSPC numbers or AMD3100-induced mobilization 
were not affected by the genetic MMP9 deficiency or by the MMP 
blockade. CWHM-823–induced mobilization was equally potent in 
FVB WT and FVB MMP9-KO mice and was not affected by bati-
Figure 4. CXCR2 expression in both the hematopoietic and nonhematopoietic (stromal) compartment contributes to tGro-induced mobilization. (A) Hemato-
poietic-specific CXCR2-KO mice were generated by transplanting lethally irradiated CD45.1+ recipients (BALB/cJ) with CD45.2+ BM cells isolated from CXCR2-KO 
mice (BALB/c, 1 × 106 cells per recipient, n = 3 BM donor mice). A control group was reconstituted with CD45.2+ WT BM cells (BALB/c, 1 × 106 cells per recipient,  
n = 3 BM donor mice). Stromal-specific knockouts were generated by transplanting CD45.1+ WT BM cells (BALB/cJ, 1 × 106 cells per recipient, n = 3 BM donors) into 
CXCR2-KO mice (CD45.2+). In the corresponding control group, WT CD45.2+ recipients were transplanted with the WT CD45.1+ BM graft. (B–D) Three months after 
transplantation, circulating HSPC numbers (Lin-kit+ cells) were assessed in the different recipients at baseline and following mobilization with CWHM-823 alone 
(3 mg/kg, 1 hour after s.c. injection, B), tGro-? alone (2.5 mg/kg, 15 minutes after s.c. injection, C), and both agents combined (dosed as indicated for separate 
treatments, 30 minutes after simultaneous s.c. injection, D). Each bar is mean ± SEM, n = 4–5. ***P < 0.001, **P < 0.01, *P < 0.05. (E) Lethally irradiated CXCR2fl/fl 
Cdh5Cre+ hosts (C57BL/6 background, CD45.2+) were reconstituted with syngeneic WT CD45.1+ BM (3 × 106 cells per recipient) to generate EC-specific knockout 
recipients. In the control group, CXCR2fl/+Cre+ and CXCR2+/+ Cre+ mice were used as recipients. Three months after transplantation, circulating HSPC (CFU-C) 
numbers were quantified at baseline and following mobilization with CWHM-823 alone (3 mg/kg, 1 hour after s.c. injection), tGro-? alone (2.5 mg/kg, 15 minutes 
after s.c. injection), and both agents combined (dosed as indicated for separate treatment, 30 minutes after simultaneous s.c. injection). Each bar is mean ± SEM, 
n = 6. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni’s adjustment for multiple comparisons. Logarithm transformation 
was performed for the data in D and E.
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of MMP9 in CWHM-823 plus tGro-?–associated augmented mobi-
lization. Rather, they suggest differences in the mechanism under-
lying mobilization induced by combining CXCR2 stimulation and 
VLA4 blockade compared with CXCR2 activation in conjunction 
with CXCR4 blockade.
Discussion
In the current study, a novel mobilization strategy, CXCR2 stimu-
lation combined with inhibition of the VLA4 integrin, was inves-
tigated and found to result in a rapid, synergistic, and highly effi-
cient recruitment of HSPCs into the circulation. Implementation 
of VLA4 antagonists with improved properties allowed for compre-
hensive testing and optimization of mobilization achieved through 
VLA4 targeting. This revealed VLA4 as a promising target associ-
ated with mobilization of a clinically relevant magnitude. Com-
pared with mobilization with G-CSF, long-term serially repopulat-
ing HSCs were relatively more strongly enriched in VLA4 inhibitor 
plus CXCR2 agonist–mobilized grafts than clonogenic cells without 
long-term repopulating capacity, indicating preferential targeting of 
a very immature HSPC fraction. Given how brisk the mobilization 
occurred and assuming BM sinusoids as the exit route for HSCs, 
our findings support the notion of a close proximity of the mobili-
zation-sensitive HSCs to BM sinusoids. Moreover, the numbers of 
rapidly mobilizable HSCs markedly exceeded previous estimates. 
Furthermore, we found an unexpected contribution of stromal 
(endothelial) CXCR2 to the mobilization induced by tGro-? alone 
as well as by VLA4 antagonist plus tGro-?, hinting at a previously 
unsuspected crosstalk between granulocytes and stroma as a mas-
ter regulator of HSPC localization and egress.
The cytokine G-CSF and chemotherapy-triggered myeloid 
rebound, the 2 commonly utilized clinical mobilization regimens, are 
comprised of 2 partly overlapping steps, proliferation and the actual 
release of the HSPCs from the BM (53, 54). Although not necessary 
nor sufficient for mobilization per se, proliferation (and therefore 
expansion) of HSPCs clearly contributes to the magnitude of G-CSF 
and chemotherapy-induced HSPC mobilization (55). In addition 
to the obvious increase in numbers, HSPC localization has been 
reported to change over the course of proliferation, favoring closer 
proximity to the vessels, which in turn facilitates BM exit (56, 57). In 
comparison, the rapid kinetics of mobilization with VLA4 antago-
nist plus tGro-? (peak reached within 15–30 minutes of s.c. injection) 
would not allow for cell division to occur prior to the HSPC release 
from the BM. Therefore, the relative enrichment for primitive, seri-
ally repopulating units in the VLA4 antagonist plus tGro-?–mobilized 
blood grafts likely reflects their preferential targeting and a pref-
erential vascular (sinusoidal) localization. Compared with G-CSF 
and chemotherapy, much less severe alterations in the BM composi-
tion in the course of VLA4 antagonist plus tGro-?–mediated mobili-
zation are to be expected, which is particularly important in light of 
the very similar potency.
Mature hematopoietic cells contained in the transplant have 
been shown to directly influence HSPC engraftment. For exam-
ple, the presence of regulatory T cells was demonstrated to ensure 
HSPC survival and colonization of the host BM (58). Also, bystand-
er effects of the myeloid compartment, granulocytes in particular, 
for the establishment of the niche following irradiation/transplan-
tation were recently described (59). Thus, granulocyte-derived 
mastat. However, mobilization was stronger in B6 MMP9-KO mice 
than in their WT counterparts. Conversely, tGro-?– and AMD3100 
plus tGro-?–induced mobilization was significantly reduced in FVB 
MMP9-KO mice or following MMP inhibitor treatment, but it was 
not altered in B6 MMP9-KO  mice. Interestingly, the combination 
of CWHM-823 plus tGro-? mobilized with equal efficiency in both 
knockout strains relative to WT control mice, whereas mobilization 
was slightly, but not significantly, reduced in mice pretreated with 
batimastat. Taken together, these data do not support a clear role 
Figure 5. Role of cell adhesion on mobilization. (A–C) Mobilization in LFA1 
(CD11a) and Mac1 (CD11b) knockout mice. CD11a-KO and CD11b-KO as well as 
WT C57BL/6J mice received an injection of PBS, tGro-? (2.5 mg/kg, s.c., time 
point 15 minutes), CWHM-823 (3.0 mg/kg, s.c., time point 60 minutes), or the 
2 agents combined (dosed the same as for separate treatments, time point 
30 minutes). Mobilization of WBCs (A), neutrophils (NEs) (B), and CFU-Cs (C) 
was assessed. Each bar is mean ± SEM, n = 4–8. ***P < 0.001, **P < 0.01, *P < 
0.05. Statistical comparisons were made using ANOVA, followed by step-down 
Bonferroni’s adjustment for multiple comparisons.
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partments, stroma or hematopoietic cells, was in fact sufficient to 
elicit HSPC egress when the combination of CWHM-823 plus 
tGro-? was used, were very much surprising. Thus, while the pres-
ence of granulocytes was necessary for both, tGro-? and CWHM-
823 plus tGro-?–induced mobilization, lack of CXCR2 expression 
on their surface seemed, to a large extent, to be compensated for 
in the case of CWHM-823 plus tGro-? treatment, as long as the 
stromal CXCR2 was present.
Relevant for the interactions between HSPC and neutrophils, 
a role of CXCR2 expression in endothelia has been increasingly 
recognized. Accordingly, CXCR2 expression in ECs of the lung 
vessels and its involvement in controlling neutrophil passage from 
the circulation into the lung parenchyma have been described 
(38). CXCR2 signaling has also been shown to critically mediate 
EC proliferation and therefore vascular repair after transplanta-
tion (39). Moreover, involvement of the zebrafish CXCR2 ortholog 
CXCR1 in the hematopoietic stem cell niche remodeling during 
embryogenesis has been demonstrated (61). Our findings along 
with the results of a companion study (unpublished observations) 
imply an additional, immediate role of endothelial CXCR2 in the reg-
ulation of HSPC retention versus egress.
Significant controversy surrounds the role of matrix metal-
loproteases in general and MMP9 in particular for mobilization 
regimens involving neutrophil stimulation such as tGro-?, IL-8, or 
TNF-? was shown to facilitate vasculogenesis, a critical step during 
regeneration. Given the high percentage as well as the direct stim-
ulation of neutrophils in VLA4 antagonist plus tGro-?–mobilized 
(and also G-CSF–mobilized) blood specimens, it is conceivable 
that granulocyte-derived factors contribute to the superior perfor-
mance of the corresponding grafts. While not excluding this possi-
bility, the results of our LSK gene expression profiling further imply 
inherent differences in the profile and composition of the differen-
tially mobilized versus BM resident HSPC populations themselves. 
In line with the idea that differences within the HSPC fraction (i.e., a 
higher proportion of more immature, serially repopulating cells) are 
primarily responsible for the observed graft fitness, LSK SLAM cells 
purified from AMD3100 plus tGro-?–mobilized blood (a regimen 
very similar to ours) were found to outperform those isolated from 
G-CSF–treated blood donors when both were tested head-to-head 
in a competitive transplant assay against BM cells (52).
Neutrophils have been demonstrated to be indispensable for 
IL-8–induced (and G-CSF–induced) mobilization (51, 60). There-
fore, our observation of a significant reduction of tGro-? as well as 
CWHM-823 plus tGro-?–associated mobilization in the context 
of granulocyte deficiency was in line with expectations. By con-
trast, the subsequent findings that nonhematopoietic CXCR2- 
expressing cells coregulate HSPC egress triggered by tGro-? alone 
and that the presence of the receptor in either one of the com-
Figure 6. Proposed mechanisms for targeting CXCR2 and VLA4 to mobilize hematopoietic stem cells. (A–D) Schematic presentation of HSPC and mature hema-
topoietic cell (NE) localization in the BM relative to the vasculature. Adhesive interactions and cellular distribution are shown under steady state (A) compared with 
following mobilization with a VLA4 antagonist (B), CXCR2 agonist (C), and the combination of the 2 strategies (D). For a detailed description see the Discussion.
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Finally, when tGro-? is combined with a second stimulus in 
the form of VLA4 inhibition, in addition to the reciprocal stimu-
lation of CXCR2-expressing cells, the associated changes in per-
meability and cell contact and/or soluble mediator decreased 
HSPC retention, which is further hit by lack of VLA4 signaling 
(Figure 6D). As demonstrated by the results of the serial com-
petitive transplantation analysis, this combination of events 
indeed recruited with high efficiency highly engraftable, true 
HSCs into the circulation. Cross-stimulation of tGro-? targeted 
cells that were dependent on integrin interactions, and blockade 
of both VLA4 and either LFA1 or Mac1 appears to disturb roll-
ing and adhesion and therefore proximity of CXCR2-expressing 
cells to an extent that cannot be compensated, unlike when 
tGro-? is given alone. This concept could explain the relatively 
less efficient mobilization with VLA4 antagonist plus tGro-? in 
mice lacking beta 2 integrins.
In summary, we show that simultaneous administration of 
CXCR2 agonists in conjunction with VLA4 small-molecule inhib-
itors results in rapid and robust mobilization of HPCs and HSCs. 
A contribution of hematopoietic (neutrophils) and nonhematopoi-
etic (endothelial) CXCR2 to the mobilization response was found. 
Grafts mobilized with the VLA4 inhibitor plus tGro-? combination 
exhibited serial repopulating capacity. Given several advantages 
of this combination over currently approved HSPC mobilization 
methods, it represents an exciting potential strategy for clinical 
development in the future. We are continuing to optimize the 
pharmacokinetic and pharmacodynamic properties of the VLA4 
inhibitors to enable future large-animal efficacy and toxicology 
studies in nonhuman primates, which are currently underway. 
Further, our data support the proposed perisinusoidal localization 
of very primitive (true) HSCs and will also serve as a tool to learn 
more about the interplay between mature hematopoietic cells, 
nonhematopoietic stroma, and stem cells.
Methods
Mice
Male 6- to 12-week-old WT BALB/cJ (CD45.2+), BALB/cByJ (CD45.2+), 
and syngeneic CByJ.SJL(B6)-Ptprca/J (CD45.1+) as well as WT 
C57BL/6J and syngeneic B6.SJL-Ptprca Pep3b/BoyJ (CD45.1+), WT 
DBA/2J, and FVB/NJ mice were purchased from the Jackson Labora-
tory. The knockout strains C.129S2(B6)-Cxcr2tm1Mwm/J (CXCR2-
KO, BALB/cJ background), B6.FVB(Cg)-Mmp9tm1Tvu/J (MMP9-KO, 
C57BL/6J background), FVB.Cg-Mmp9tm1Tvu/J (MMP9-KO, FVB/
NJ background), B6.129S7-Itgaltm1Bll/J (CD11a-KO, C57BL/6J back-
ground), and B6.129S4-Itgamtm1Myd/J (CD11b-KO, C57BL/6J back-
ground) were also obtained from Jackson Laboratory. Endothelial- 
specific CXCR2 ablated mice were generated by crossing C57BL/6- 
Cxcr2tm1Rmra/J (CXCR2fl/fl, Jackson Laboratory) and B6;129-Tg 
(Cdh5-cre)1Spe/J (Cdh5Cre, Jackson Laboratory) mice. Mobilization 
experiments were performed with Cxcr2fl/flCre+ mice (CXCR2fl/WTCre+ 
were used as controls) reconstituted with WT BM from syngeneic 
B6.SJL-Ptprca Pep3b/BoyJ (CD45.1+, Jackson Laboratory) donors. Fol-
lowing lethal irradiation (1× 9.5–11 Gy, using a cesium source) and 
transplantation, mice were kept on 0.5 mg/ml sulfamethoxazole 
and 0.1 mg/ml trimethoprim (HI-Tech Pharmacal), administered by 
mouth in drinking water.
G-CSF. In a recent study by Hoggatt et al. describing a mobilization 
approach similar to ours (AMD3100 plus tGro-?, ref. 52) the authors 
reported a contribution of MMP9 activity to the synergistic mobili-
zation response in mice. Moreover, a correlation between mobiliza-
tion efficiency in healthy G-CSF donors and activity of the MMP9 
inhibitor TIMP1 was described. In our analysis, a trend toward 
a more pronounced contribution of MMP9 during HSPC egress 
induced by AMD3100 plus tGro-? as compared with CWHM-823 
plus tGro-? was observed. However, a requirement for intact MMP9 
for a tGro-?–based regimen could not be corroborated.
The differences in the magnitude and kinetics of HSPC egress 
associated with the different regimens analyzed in this study, as 
well as the distinct properties of cells mobilized with VLA4 antag-
onists alone, versus tGro-? alone, versus VLA4 antagonist plus 
tGro-?, can be interpreted as a result of targeting distinct HSPC 
subsets (Figure 6A–D). Thus, based on their performance in the 
competitive transplantation setting (Figure 2, A–C), more mature 
progenitor cells are primarily mobilized with a VLA4 antago-
nist alone (Figure 6B). Expression of the beta 2 integrins LFA1 
and Mac1 on human and murine hematopoietic progenitor cells 
(HPCs) but not stem cells has been demonstrated (48, 62). Hence, 
although not markedly dislodging stem cells when blocked indi-
vidually, inhibition of LFA1 or Mac1 in conjunction with VLA4 
blockade resulted in enhanced HPC mobilization. Consistent with 
the direct mode of action of VLA4 antagonists (4, 63), loss of gran-
ulocytes did not affect VLA4 inhibitor–induced HSPC egress.
Peak mobilization after tGro-? treatment is remarkably fast. 
Activation of CXCR2 signaling in ECs has been reported to lead to 
EC contraction (64, 65) and weakening of intercellular junctions 
(66, 67). In accordance with these reports, we detected increased 
permeability of vascular cells after CXCR2 stimulation in vivo and 
in vitro (unpublished observations). Increased vascular leakiness has 
also been found in the BM of tGro-?–treated mice (52) and is likely a 
major contributor to the brisk kinetics of tGro-?–triggered HSPC emi-
gration (Figure 6C). Moreover, though not addressed in our analysis 
directly, an involvement of the complement cascade, a key orchestra-
tor of pharmacologically and pathologically induced HSPC release 
from the BM (68, 69), and the associated release of anaphylatoxins 
might have facilitated increased vascular permeability. The latter are 
further known to stimulate the release of the lipolytic enzyme phos-
pholipase C ?2 (PLCB2), which in turn disrupts the lipid raft forma-
tion needed for optimal signaling via VLA4 and CXCR4 (68, 70).
Adhesive interactions and cross-stimulation between CXCR2- 
expressing granulocytes and endothelia are critical for the 
increased permeability and likely also for the subsequent cell-cell 
contact or soluble mediator-enabled HSPC release in the con-
text of mobilization with tGro-? alone. However, in contrast to 
the reported requirement of LFA1 for IL-8–induced mobilization 
(19), neither deficiency for LFA1 nor for Mac1 enhanced tGro-?–
mediated HSPC egress. Loss of one beta 2 integrin was possibly 
compensated for by the presence of the other, along with other 
integrins. With regard to the HSPC population targeted, the trans-
plant data suggested predominant mobilization of progenitor cells 
with tGro-?, as was the case with VLA4 antagonist alone. Hence, 
elevated vascular permeability and reduced retention induced by 
tGro-? alone are not sufficient to release the HSCs from their pro-
tective BM environment.
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Induction of diabetes
Diabetes was induced in 8-week-old BALB/cJ mice by a single i.p. injec-
tion of 200 mg/kg streptozotocin (SZT, EMD Millipore) dissolved 
in citrate buffer (pH 4.7–5.3, Sigma-Aldrich). Blood glucose levels 
were measured with a portable blood glucose meter (Glucocard Vital, 
ARKRAY USA Inc.). Animals with glucose values higher than 300 mg/dl 
were used for mobilization experiments 2–3 weeks after SZT injection.
Transplantation
Serial competitive transplantation. Lethally irradiated CD45.2+ BALB/cJ 
hosts received i.v. transplants consisting of 2.5 × 105 CD45.2+ BM cells 
and a small volume (10 ?l) of differentially mobilized blood (BALB/cJ 
CD45.1+: G-CSF for 5 days vs. tGro-? vs. VLA4 antagonist firategrast 
or CWHM-823 vs. VLA4 antagonist plus tGro-?). Twenty weeks after 
the transplantation, PB composition of the recipients was analyzed for 
the presence of blood graft–derived hematopoiesis (i.e. percent con-
tribution of blood donor CD45.1+ cells within the CD45+CD3– com-
partment). Following PB analysis, BM cells of the primary recipients 
were isolated and pooled based on WBC counts at equal proportion 
per recipient per group (G-CSF and both VLA4 antagonist plus tGro-? 
groups). Primary recipient BM cell mixture (2.5 × 106 per mouse) was 
injected into lethally irradiated secondary recipients (CD45.2+). PB 
analysis of secondary hosts was performed 18 weeks after the trans-
plantation. Similarly, CD45.1+ percentage within the CD45+CD3– frac-
tion was determined.
Generation of transplantation chimeras for mobilization. To generate 
hematopoietic specific CXCR2-KO mice, 1 × 106 BM cells from CXCR2-
KO animals (CD45.2+) were transplanted into lethally irradiated WT 
syngeneic BALB/cJ CD45.1+ recipients. Control group of CD45.1+ hosts 
received WT CD45.2+ BM cells. Conversely, stromal-specific knock-
outs were generated by transplanting lethally irradiated CXCR2-KO 
animals with 1 × 106 CD45.1+ WT BM cells. In the corresponding con-
trol group, WT CD45.2+ hosts received CD45.1+ BM grafts.
For EC-specific CXCR2 ablation, lethally irradiated CXCR2fl/fl 
Cdh5Cre+ hosts (C57BL/6 background, CD45.2+) were reconstituted 
with syngeneic WT CD45.1+ BM (3 × 106 cells per recipient). In the 
control group CXCR2fl/WTCre+ and CXCR2WT/WT Cre+ mice were used 
as recipients.
Mobilization studies in chimeric animals were started 8–12 weeks 
after the transplantation. Lack of contribution of recipient endoge-
nous hematopoiesis was verified by flow cytometry in each recipient.
Fluorescence activated cell analysis and sorting (FACS)
Cell labeling was performed according to standard protocols using 
established marker panels for identification of different subsets 
in mouse hematopoietic tissues as previously described (10, 12). 
Lineage-negative and c-Kit–positive (Lin– kit+) or lineage-negative, 
Sca-1–positive and c-Kit–positive cells (LSK cells) were an estimate 
for HSPCs, whereas HSCs were identified as LSK SLAM (LSK CD150+ 
CD48–) cells. Antibodies used in this study are listed in Supplemen-
tal Table 6. Sample acquisition was performed on Gallios (Beckman 
Coulter Life Sciences) and BD LSRFortessa (BD Biosciences) flow 
cytometers or BD FACS Aria II cell sorter (BD Biosciences). Data 
were further analyzed using FlowJo software (Tree Star) or FACS-
Diva software (BD Biosciences). Cell isolation by flow sorting was 
performed on BD FACS Aria II. Cell-cycle analysis was performed as 
previously described (10, 12).
Cell and tissue preparation
Peripheral blood (PB) and BM cells were recovered as previously 
described (12). Cell counts (WBC) were measured on an automatic 
hemocytometer (Hemavet 950, Drew Scientific). Total counts (per 
tissue) as well as the majority of functional analysis were performed 
with filtered and otherwise unmanipulated cell suspensions, whereas 
red cells were removed from suspensions prepared for flow cytom-
etry using hypotonic lysis. Absolute numbers of immunophenotyp-
ically defined populations (e.g., LSK cells) were calculated assum-
ing CD45+ cells are equivalent to WBC from the corresponding 
cell count analysis.
In vivo reagents and treatments
Human recombinant truncated Gro-? peptide (tGro-?, CXCL2, 
SB-251353 from GlaxoSmithKline) was used for all in vivo experi-
ments. Stock solution stored at –80°C was freshly thawed and diluted 
immediately prior to the s.c. injection (2.5 mg/kg) (52). Murine 
recombinant CXCL1 (PeproTech) and human recombinant CXCL8 
(aa 23-99, Sino Biological) stock solutions were prepared in water. 
All chemokines were diluted in PBS (GE Healthcare Life Scienc-
es) or used directly in the CWHM-823 solution. CWHM-823 plus 
chemokine mixtures were sonicated in a water bath for 15–30 min-
utes prior to injection to counteract precipitation. Firategrast was 
synthesized based on the published structure (C27H27F2NO6; patent 
no. US2014051655), dissolved in a 1% ethanol solution in PBS and 
injected i.v. or s.c. (100 mg/kg). Mice treated with firategrast plus 
tGro-? received 2 separate injections. All other VLA4 antagonists, 
BIO5192 (TOCRIS, Bio-Techne Corporation) (28), CWHM-842, 
-822, -823, -824, and -825 were dissolved in DMSO (100× stock 
solution) and diluted in NaHCO3/NaCl buffer (1:1, 10 mM NaHCO3, 
pH 8; 0.9% wt/vol NaCl) for subsequent i.v., s.c. (CWHM-823 only), 
or i.p. (CWHM-823 only) injection at 3 mg/kg. BIO5192 plus tGro-? 
and CWHM-842 plus tGro-? treatment consisted of 2 separate 
injections, whereas CWHM-823 plus Gro-? was administered either 
as 2 injections (VLA4 antagonist i.v., tGro-? s.c.) or as one injec-
tion (i.v., i.p., or s.c.) as specified for each experiment. AMD3100 
(Mozobil, Genzyme) suspension was prepared in PBS and adminis-
tered s.c. (5 mg/kg). AMD3100 plus tGro-? mixture was prepared 
by diluting tGro-? in the AMD3100 solution and then s.c. injected. 
RhG-CSF (Neupogen, Filgrastim, Amgen) diluted in PBS was 
in jected i.p. every 12 hours at a dose of 100 ?g/kg for a total of 4 
(day 3) or 9 (day 5) doses. Broad spectrum matrix metalloprotease 
inhibitor batimastat (BB-94, APExBio) was dissolved in DMSO, 
diluted in corn oil (Sigma-Aldrich), vortexed thoroughly, and inject-
ed i.p. 12 and 2 hours (25 mg/kg) prior to the mobilization treat-
ment. Control mice received DMSO/corn oil injections. In all other 
experiments, mice injected with PBS, PBS/DMSO, or left untreated 
(baseline) at the time point of analysis are referred to as control 
animals throughout the manuscript.
Depletion of granulocytes
To deplete granulocytes in vivo the anti-mouse Ly6G/Ly6C anti-
body (Gr1, clone RB6-8C5, BioXCell) was administered i.v. (200 ?g/
mouse) 36 hours prior to the mobilization treatment. Control mice 
were treated with an isotype control antibody (clone 2A3, BioXCell). 
Efficient depletion of peripheral blood granulocytes was confirmed 
using differential blood count as well as flow cytometric analysis.
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Water solubility assay
For each VLA4 antagonist tested, 1–2 mg solid compound was placed 
in an Eppendorf tube with 1 ml equilibrium solubility buffer (ESB, 50 
mM citric acid, 50 mM K2HPO4, 50 mM Ammediol, and 50 mM KCl, 
pH 7) and incubated in a Thermomixer for 48 hours at 25°C at 500 rpm. 
After 24 hours, tubes were centrifuged at 3000g for 5 minutes, and an 
aliquot of the supernatant was removed and diluted into linear stan-
dard range of the standard curve for the LCMS method. Sample dilu-
tions and standards were made in 75:25 ESB/acetonitrile. Firategrast, 
BIO5192, CWHM-823, CWHM-824, CWHM-825, and CWHM-842 
concentrations were determined on a Sciex API-4000 LC/MS system 
(SCIEX) in positive electrospray mode. Analytes were eluted from an 
Armor C18 reverse phase column (2.1 × 30 mm, 5 ?m) using a 0.1% 
formic acid mobile phase system with aqueous to acetonitrile gradient 
over 3.7 minutes at a flow rate of 0.35 ml/min. Peak areas for the mass 
transition of m/z 500.3 > 454.2 for firategrast, m/z 817.2 > 394.0 for 
BIO5192, m/z 505.0 > 176.0 for CWHM-822, m/z 518.0 > 472.2 for 
CWHM-823, m/z 621.2 > 575.0 for CWHM-824, m/z 474.6 > 192.2 for 
CWHM-825, and m/z 523.4 > 390.2 for CWHM-842 were integrated 
using Analyst 1.5.1 software (SCIEX). Peak areas were plotted against 
standard concentrations with a 1/x-weighted linear regression.
VCAM1 binding assay
G2 ALL cells (1.5 × 105 cells per sample, The Hospital for Sick Children) 
were incubated with increasing concentrations of the different VLA4 
antagonists for 30 minutes at room temperature (RT). Subsequently, 
human recombinant VCAM1/Fc chimera protein (R&D Systems) was 
added to the samples at a final concentration of 10 ?g/ml. After a sec-
ond 30-minute incubation step at RT, cells were washed twice with 
HBSS/0.1% BSA buffer and secondary antibody (PE-labeled donkey 
anti-human IgG, catalog 709-116-098, Jackson Immunoresearch Lab-
oratories) added at 1:100 dilution. Control samples were stained with 
PE-labeled donkey IgG (catalog 017-110-006, Jackson Immunore-
search Laboratories, 1:100 dilution). Secondary antibody staining was 
performed at RT for 30 minutes. Following addition of 7-AAD for 5 
minutes at RT, cells were washed twice with HBSS/BSA buffer and 
analyzed by flow cytometry.
Integrin binding assay
The potency of compounds in blocking ligand binding to integrins 
a4b1 and a4b7 was determined by modification of our previously 
described methods (71). Briefly, purified human VCAM1 (R&D 
Systems) diluted to 5 ?g/ml in TBS+ buffer (25 mM Tris pH 7.4, 137 
mM NaCl, 2.7 mM KCl, 1mM CaCl2, 1 mM MgCl2, 1 mM MnCl2) was 
added to wells of a 96-well transparent microtiter plate and incu-
bated overnight at 4°C. Wells were washed 3 times with TBS+ and 
blocking buffer (TBS+ with 1% bovine serum albumin), the plate was 
incubated for 1 hour at 37°C, and then washed 3 times with TBS+ 
buffer. Recombinant human integrin ITGA4/ITGB1 (?4?1; VLA4) 
or ITGA4/ITGB7 (?4?7) (R&D Systems) was diluted to 1 ?g/ml in 
TBS+/0.1% bovine serum albumin. Test compounds were diluted 
into the integrin solution and added to the washed ligand-coated 
plate according to a standard template with each sample repeat-
ed in triplicate. After incubation for 2 hours at room temperature, 
the plate was washed 3 times with 150 ?l TBS+ buffer. To each well, 
biotinylated anti-?1 (catalog BAF1778, R&D Systems) or anti-?4 
antibody (clone 7.2R, R&D Systems) at 1 ?g/ml in TBS+/0.1% BSA 
Colony-forming unit assay
Cells were incubated in duplicate in commercially available growth 
factor supplemented with methylcellulose medium for mouse 
CFU-Cs (Stem Cell Technologies or R&D Systems) as described (10, 
12). CFU-Cs (BFU-E, CFU-GM, and CFU-GEMM) were enumerated 
after 6–8 days of culture.
Quantitative real-time PCR
For analysis of gene expression in cell populations (LSK, LSK SLAM, 
and different mature cell fractions) sorted from the BM RNA was 
isolated using RNA XS column kit (Machery-Nagel). Ambion Turbo 
DNA-free Kit (Thermo Fisher Scientific) was then used to remove 
genomic DNA followed by reverse transcription of the RNA using the 
QuantiTect Reverse Transcription Kit (Qiagen). qRT-PCR (Cxcr2 and 
Gapdh) was performed using TaqMan Master Mix, probes and primers 
(Applied Biosystems) listed in Supplemental Table 7.
Microarray analysis
RNA from LSK cells sorted from untreated BM or PB of differen-
tially mobilized (G-CSF [5 days], AMD3100, or CWHM-823 plus 
Gro-?; single injection) mice was prepared using the RNA XS column 
kit (Macherey-Nagel) and hybridized to the Mouse Gene Expres-
sion v2 4×44K microarray (Agilent Technologies). Normalization 
and quality assessment of expression data were performed using 
Partek Genomic Suite (Partek Inc.). Thus, log2 scale-transformed 
and filtered expression data were used for PCA plot generation. 
Hierarchical clustering was performed using the top 1000 differ-
entially (significance) regulated genes. All original microarray data 
were deposited in the NCBI’s Gene Expression Omnibus database 
(GSE123505) and expression data can be accessed at https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123505.
Pharmacokinetics
PB was drawn from the facial vein without anesthesia and collected 
into lithium heparin anticoagulated tubes (Sarstedt AG & Co). 
If not processed immediately, samples were stored on ice (approx-
imately 1 hour). After centrifugation (25 minutes, 800–1500g, 4°C) 
plasma supernatant was carefully removed, frozen, and stored 
at –80°C until just before analysis. Plasma samples or standards 
prepared in plasma matrix (50 ?l) were added to a 96-well plate. 
To each well, 200 ?l cold acetonitrile containing 100 ng/ml 
extraction internal standard enalapril was added. The plate was 
vor texed for 5 minutes, and then centrifuged at 1600g for 5 min-
utes at 4°C. The supernatant (200 ?l) was transferred to a second 
96-well plate, evaporated to dryness under nitrogen, reconstituted 
with 100 ?l of 0.1% vol/vol formic acid in 9:1 water/acetonitrile, 
vortexed for 5 minutes, and the samples were analyzed by LC/
MS. CWHM-823 concentrations were determined on a Sciex 
API-4000 LC/MS system (SCIEX) in positive electrospray mode. 
Analytes were eluted from an Armor C18 reverse phase column 
(2.1 × 30 mm, 5 ?m) using a 0.1% formic acid mobile phase system 
with aqueous to acetonitrile gradient over 3.7 minutes at a flow rate 
of 0.35 ml/min. Peak areas for the mass transition of m/z 518 > 472 
for CWHM-823 and m/z 376 > 91 for enalapril (IS) were integrated 
using Analyst 1.5.1 software. Peak area ratios of CWHM-823 area/
enalapril area were plotted against standard concentrations with a 
1/x-weighted linear regression.
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was added and the plate covered and incubated for 1 hour at RT. 
After washing the plate 3 times with TBS+ buffer, streptavidin- 
conjugated horseradish peroxidase (R&D Systems) diluted in TBS+ 
blocking buffer was added to the wells and the plate incubated for 
20 minutes at room temperature. The plate was washed 3 times 
with TBS+ buffer followed by addition of 50 ?l TMB substrate 
(MilliporeSigma). After incubation for 20 minutes at RT, plates were 
read by colorimetric detection at 650 nm wavelength using a Tecan 
Safire II plate reader. Concentration-response curves were con-
structed by nonlinear regression (best fit) analysis, and IC50 values 
were calculated for each compound.
To evaluate the broader selectivity of test compounds, potency 
against a nontargeted beta-1 subunit–containing integrin, ITGA2/
ITGB1 (?2?1), was measured as previously described (71). Assess-
ment of compound potency against 2 selected members of the 
RGD-binding integrin family, ITGA5/ITGB1 (?5?1) and ITGAV/
ITGB3 (?v?3), was determined by a similar method in which bind-
ing of the purified human integrins (R&D Systems) was assessed 
to plates coated with their respective purified ligands, human 
fibronectin (2 ?g/ml, R&D Systems) and human vitronectin (1 ?g/
ml; R&D Systems). Biotinylated anti-ITGAV (?v) or anti-ITGA5 
(?5; R&D Systems) antibodies were used to detect the stably bound 
integrins in conjunction with streptavidin-conjugated horseradish 
peroxidase as described above. The ?v?3 and ?5?1 assays were val-
idated by inclusion of a known potent inhibitor of these integrins, 
CWHM-12 (71), while the ?2?1 assay was validated by inclusion 
of another previously described inhibitor, compound 8 (data not 
shown) (72).
Specificity screening
tGro-? was sent out to DiscoverX (DiscoverX Corporation) for blinded 
profiling against the gpcrMAX panel (148 G protein–coupled receptors 
screened in both, agonist and antagonist mode) using the PathHunter 
beta-arrestin enzyme fragmentation (EFC) technology.
Statistics
Data are mean ± SEM unless indicated otherwise. Linear mixed 
models were used to analyze experiments with data repeatedly 
measured from the same mice, while analysis of variance (ANOVA) 
was used for data from independent samples. A logarithm transfor-
mation was performed as necessary to better satisfy the normality 
and homoscedasticity assumptions (see Figure legends for details). 
Ad-hoc multiple comparisons were also used for between-group dif-
ferences of interest. The resultant P values were adjusted by Holm’s 
step-down Bonferroni’s adjustment. Compared with the widely used 
Bonferroni’s adjustment, a step-down method is more powerful 
(smaller adjusted P values) while maintaining strong control of the 
familywise error rate. All analyses were 2-sided and significance was 
set at a P value of 0.05. The statistical analyses were performed using 
SAS 9.4 (SAS Institutes).
Study approval
All animals were housed at the Washington University Medical School 
vivarium under SPF conditions with autoclaved chow and water ad 
libitum. All experiments were performed in accordance with the 
guidelines of the Washington University Animal Studies Committee, 
approved by the IACUC in agreement with AAALAC guidelines.
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